Lyell Immunopharma
South San Francisco · Founded 2018
About Lyell Immunopharma
Lyell is a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors. Lyell focuses on addressing what it believes are the primary barriers that limit consistent, reliable and curative responses with adoptive T cell therapy: T cell exhaustion and loss of durable stemness, which includes proliferative capacity, ability to self-renew and ability to differentiate and eliminate solid tumors. Lyell is applying its proprietary ex vivo genetic and epigenetic reprogramming technology platforms, Gen-R and Epi-R, to address these barriers in order to develop new medicines with improved, durable, and potentially curative clinical outcomes.
Company Facts
- Founded: 2018
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 251 – 500
- Estimated revenue: Less than $1M
- Total funding: $593.0M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jul 2025)
- Ticker: nasdaq:LYEL
- Website: lyell.com
- Phone: 1 650-695-0677
Industries & Categories
Biotechnology, Health Care, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/lyell-immunopharma-80298 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.